Related Experiment Video

Updated: Sep 3, 2025

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening
08:14

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening

Published on: October 26, 2017

15.8K

MiRNAs in Lung Cancer: Diagnostic, Prognostic, and Therapeutic Potential

Javaid Ahmad Wani1, Sabhiya Majid1, Zuha Imtiyaz2

  • 1Department of Biochemistry, Government Medical College (GMC-Srinagar), Karan Nagar, Srinagar 190010, J&K, India.

Diagnostics (Basel, Switzerland)
|July 27, 2022
PubMed

Insights

MicroRNAs (miRNAs) show promise in diagnosing and treating lung cancer, addressing challenges like relapse and chemoresistance. Further research into miRNOME expression is crucial for developing effective anti-cancer strategies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Lung cancer remains a leading cause of global cancer mortality.
  • Current therapies face limitations due to recurrence, chemoresistance, and late diagnosis.
  • MicroRNAs (miRNAs) are key regulators of gene expression involved in tumorigenesis.

Purpose of the Study:

  • To review the therapeutic, diagnostic, and prognostic potential of miRNAs in lung cancer.
  • To highlight the necessity of exploring miRNOME expression for novel anti-cancer strategies.

Main Methods:

  • Literature review of studies on miRNA expression in lung cancer.
  • Analysis of miRNA involvement in key cancer processes (proliferation, apoptosis, metastasis, angiogenesis).

Main Results:

  • miRNAs play a significant role in lung cancer development and progression.
  • Emerging evidence supports miRNAs as biomarkers for lung cancer diagnosis and prognosis.
  • miRNAs offer potential as therapeutic targets for lung cancer treatment.

Conclusions:

  • miRNAs represent a promising avenue for improving lung cancer diagnostics and therapeutics.
  • Comprehensive understanding of the lung cancer miRNOME is essential for clinical translation.
  • Targeting miRNAs could overcome current treatment challenges like chemoresistance and relapse.
Keywords:
diagnosticslung cancermiRNAtherapeutics

More Related Videos

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

7.7K
miRNA Expression Analyses in Prostate Cancer Clinical Tissues11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

10.9K

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.1K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.8K